Blog Post

Fluorine-18 (F-18) PSMA PET-CT scans

26/05/2022

PSMA PET-CT scans are important in the detection and staging of prostate cancer. In Australia, the most commonly used tracer for PSMA PET-CT scans is Gallium-68 (Ga-68).

However, Qscan Group uses Fluorine-18 (F-18), a tracer developed by Professor Martin Pomper, director of nuclear medicine and imaging at the Johns Hopkins University School of Medicine.  

Benefits of F-18

  • Improved image quality compared to scans using Ga-68
 
  • Intrinsic physical properties, which lends an improved spatial resolution of 5mm
 
  • Longer half-life, meaning increased reliability as a tracer
 
  • Lower urinary excretion
 
  • Improves detection of recurrences and additional lesions
 
  • Improved specificity in staging
 
  • Higher tumour uptake
 
  • High sensitivity, even in small tumours
Improved confidence for EPE and SVI

An 83-year-old male with a large basal PZ tumour. SVI is not clear in the Ga-68 PSMA images (note resolution and background noise), but with F-18, SVI is clearly resolved.
Reduced false positives for M staging

Scans of a 67-year-old male showing uptake in an L2 vertebral sclerotic lesion. Ga-68 PSMA (left) only showed background noise, while F-18 PSMA (right) allowed the patient to be cleared of metastatic disease.

Qscan Group has been using F-18 as our PSMA tracer of choice since 2017.

We are the most experienced in Australia when it comes to using F-18 for PSMA imaging, and will bring this leading expertise to all your prostate patients.

PSMA PET-CT is available at all Qscan clinics that offer PET-CT services. Click here to find a clinic near you.

References:

·        Brauchli D, Singh D, Chabert C, Somasundaram A, Collie L. Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging. J Med Imaging Radiat Oncol. 2020 Dec;64(6):829-838.

·        Parathithasan N, Perry E, Taubman K, Hergarty J, Talway A, Wong L, Sutherland T. Combination of MRI prostate and 18F-DCFPyl PSMA PET/CT detects all clinically significant prostate cancers in treatment-naive patients: An international multicentre retrospective study. J Med Imaging Radiat Oncol 2022 Feb

Contact Qscan